Immunic (IMUX) Restructuring Costs (2018 - 2019)
Immunic (IMUX) posted Restructuring Costs of $6.4 million for Q1 2019, up 165.93% sequentially from $2.4 million in Q3 2018.
Powered by 
Analysis
Immunic (IMUX) Restructuring Costs (2018 - 2019) Analysis & Trends
Immunic has reported Restructuring Costs for 2 years, with the latest figure at $6.4 million in Q1 2019.
- Quarterly Restructuring Costs changed N/A year-over-year to $6.4 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $8.8 million (changed N/A YoY) and the FY2018 annual result came in at $2.4 million, changed N/A from the prior year.
- Restructuring Costs improved to $6.4 million in Q1 2019 per IMUX's latest filing, from $2.4 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $6.4 million in Q1 2019 and troughed at $2.4 million in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Immunic | 543.33 Mn | 543.33 Mn | - |